Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure.
Many clinical studies have documented favourable effects (reduced morbidity and mortality) of beta-adrenoceptor (β-AR) antagonists, such as carvedilol, metoprolol, propranolol, atenolol and bisoprolol, in congestive heart failure. These agents attenuate the effects of sympathetic activation during the development of heart failure, prevent ventricular remodelling and improve cardiac function. Because β-AR blockers are known to exert negative inotropic action, the mechanisms responsible for their beneficial effects in heart failure have been a subject of debate. While attenuation of changes in β-AR cyclic AMP-mediated signal transduction in heart failure is considered to be responsible for the beneficial effects of β-AR antagonists, other mechanisms such as the effects of these agents on subcellular remodelling, oxidative stress, apoptosis and defect in calcium handling, are equally important in preventing cardiac alterations in the failing heart. Moreover, β-AR antagonists are not a homogeneous group of drugs because they differ in their pharmacokinetics and pharmacodynamics, in addition to the selective and nonselective nature of their actions on β-AR. Various β-AR blocking agents have been shown to possess different ancillary properties and produce effects that are independent of β-AR. In fact, different β-AR antagonists have been observed to lower the elevated levels of plasma catecholamines in heart failure. Thus, the beneficial effects of β-AR antagonists are not only elicited through their interaction with mediated β-AR signal transduction sites in the myocardium, but other mechanisms may also contribute to their favourable actions in heart failure.
Institute of Cardiovascular Sciences, St Boniface Hospital Research Centre;
Navneet S
NS
Rehsia
Naranjan S
NS
Dhalla
J Clin Invest. 1985 Dec;76(6):2259-64
3001147
J Pharmacol Exp Ther. 2006 Jul;318(1):45-52
16611853
Eur Heart J. 2003 Mar;24(6):552-9
12643888
Circulation. 1999 Nov 30;100(22):2210-2
10577992
Circulation. 2004 Aug 31;110(9):1083-90
15313944
Am J Cardiol. 1997 Dec 4;80(11A):26L-40L
9412540
Clin Exp Pharmacol Physiol. 2005 Jul;32(7):553-60
16026515
Expert Opin Ther Targets. 2001 Apr;5(2):205-17
15992177
Circ Res. 1988 Jul;63(1):262-6
2898307
Eur J Pharmacol. 2007 Jul 19;567(3):223-30
17559835
Heart Fail Rev. 2000 Mar;5(1):17-25
16228913
J Am Coll Cardiol. 2007 Apr 24;49(16):1722-32
17448375
Lancet. 2003 Jul 5;362(9377):7-13
12853193
Srp Arh Celok Lek. 2005 May-Jun;133(5-6):242-7
16392280
Am J Cardiol. 1984 Oct 1;54(7):783-6
6486028
J Am Coll Cardiol. 1997 Jul;30(1):27-34
9207617
Am J Cardiol. 1997 Oct 30;80(8B):14H-27H
9372994
Stress. 2006 Jun;9(2):69-84
16895831
Circulation. 2000 Apr 11;101(14):1707-14
10758054
Chin Med J (Engl). 2009 Oct 5;122(19):2372-9
20079142
Cardiovasc Res. 1998 Oct;40(1):146-55
9876327
Cardiovasc Res. 2008 Jul 1;79(1):42-51
18310678
Cardiovasc Res. 2000 Nov;48(2):274-84
11054474
Acta Pharmacol Sin. 2004 Nov;25(11):1458-63
15525468
J Am Coll Cardiol. 2004 Apr 21;43(8):1423-9
15093878
Hypertension. 1997 Mar;29(3):715-22
9052886
Mol Cell Biochem. 1992 Sep 8;114(1-2):91-5
1461261
Expert Opin Pharmacother. 2005 Sep;6(11):1857-81
16144507
J Am Coll Cardiol. 1995 Apr;25(5):1154-61
7897129
Br J Pharmacol. 1999 Aug;127(7):1671-9
10455325
J Mol Cell Cardiol. 2006 Feb;40(2):258-66
16427077
Circulation. 2000 Feb 8;101(5):558-69
10662755
J Int Med Res. 2009 Sep-Oct;37(5):1354-64
19930840
Anesthesiology. 2008 Dec;109(6):1045-53
19034101
N Engl J Med. 1996 May 23;334(21):1349-55
8614419
J Cardiovasc Pharmacol. 2000 May;35(5):806-13
10813385
J Cell Mol Med. 2011 Mar;15(3):545-54
20082655
Auton Neurosci. 2006 Dec 30;130(1-2):6-16
16798104
Arch Mal Coeur Vaiss. 2005 Mar;98(3):236-41
15816327
Am J Ther. 2008 Nov-Dec;15(6):565-76
19127141
Eur Heart J. 2005 Feb;26(3):215-25
15642700
Basic Res Cardiol. 1984 Nov-Dec;79(6):620-6
6152393
Circulation. 2002 Mar 19;105(11):1374-9
11901051
Acta Pharmacol Sin. 2007 Aug;28(8):1161-5
17640478
J Cardiovasc Pharmacol. 2000 Aug;36(2):277-81
10942172
Eur J Pharmacol. 2008 Jul 28;589(1-3):194-200
18534575
Circulation. 2003 May 20;107(19):2459-66
12743001
Circ Res. 2008 Mar 28;102(6):633-6
18323523
Circulation. 2004 Jan 6;109(1):120-4
14662714
J Cardiovasc Pharmacol. 2001 Dec;38 Suppl 3:S13-6
11811387
Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1197-201
1705030
Cardiovasc Res. 2000 Feb;45(3):788-94
10728402
Eur J Heart Fail. 2003 Dec;5(6):725-32
14675850
Physiol Rev. 1995 Oct;75(4):725-48
7480160
J Pharmacol Exp Ther. 2007 Jul;322(1):222-7
17409273
Eur J Pharmacol. 1999 Jul 2;376(1-2):189-201
10440104
Cardiovasc Toxicol. 2010 Mar;10(1):9-16
19949891
Circulation. 2001 Oct 30;104(18):2194-9
11684630
Biochem Biophys Res Commun. 2005 Mar 4;328(1):116-24
15670758
J Cardiovasc Pharmacol. 2001 Dec;38 Suppl 3:S17-23
11811388
Circulation. 1996 Dec 1;94(11):2817-25
8941107
Cardiovasc Res. 2004 Jan 1;61(1):143-51
14732211
J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):61A-71A
8397233
J Appl Physiol (1985). 2007 Mar;102(3):978-84
17122376
Circulation. 1996 Aug 1;94(3):353-8
8759076
Cardiovasc Res. 2003 Mar;57(3):784-92
12618240
Can J Physiol Pharmacol. 2006 Jul;84(7):747-54
16998538
Circulation. 2000 Jul 18;102(3):344-50
10899100
Circ Res. 1996 Apr;78(4):517-24
8635208
J Am Coll Cardiol. 2000 Nov 1;36(5):1698-705
11079679
Chest. 2005 Sep;128(3):1812-21
16162791
J Mol Cell Cardiol. 2003 May;35(5):483-93
12738230
Circulation. 1990 Oct;82(4):1249-65
2169357
J Mol Cell Cardiol. 2008 Aug;45(2):240-9
18632114
Br J Clin Pharmacol. 2003 Feb;55(2):134-8
12580984
Ann Intern Med. 2001 Apr 3;134(7):550-60
11281737
J Clin Invest. 1998 Oct 1;102(7):1377-84
9769330
J Am Coll Cardiol. 2000 Jul;36(1):276-81
10898446
Cardiovasc Drugs Ther. 2007 Apr;21(2):85-90
17440824
Auton Autacoid Pharmacol. 2002 Oct-Dec;22(5-6):261-8
12866806
Cardiovasc Drugs Ther. 2008 Oct;22(5):399-405
18528751
Circulation. 2002 Aug 13;106(7):793-7
12176949
J Clin Invest. 2003 Mar;111(5):617-25
12618516
Zhonghua Xin Xue Guan Bing Za Zhi. 2007 May;35(5):476-9
17711695
Circ J. 2003 Jan;67(1):83-90
12520158
Lancet. 2001 May 5;357(9266):1385-90
11356434
Circulation. 2000 May 2;101(17):2103-9
10790354
Br J Pharmacol. 1980;71(2):435-44
6258697
Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1003-12
15105169
Cardiovasc Drugs Ther. 2002 Sep;16(5):443-9
12652114
Circ Res. 1986 Sep;59(3):297-309
2876788
Am J Cardiol. 2007 Aug 15;100(4):690-6
17697830
BMC Chem Biol. 2008 Aug 01;8:2
18673549
J Mol Cell Cardiol. 1991 Nov;23(11):1231-44
1687065
Hypertension. 2007 Oct;50(4):652-6
17664392
Can J Physiol Pharmacol. 2009 Jul;87(7):493-514
19767873
Lancet. 1999 Jan 2;353(9146):9-13
10023943
JAMA. 2000 Mar 8;283(10):1295-302
10714728
J Cardiovasc Pharmacol Ther. 2004 Dec;9(4):243-55
15678243
Circ J. 2006 Mar;70(3):321-6
16501300
Circ Res. 1966 Aug;19(2):317-25
5914846
J Huazhong Univ Sci Technolog Med Sci. 2004;24(5):433-6
15641685
Cardiology. 2009;112(4):294-302
18832825
J Cardiovasc Pharmacol Ther. 2003 Sep;8(3):207-15
14506546
Jpn Heart J. 2003 Nov;44(6):979-88
14711192
Eur J Clin Invest. 1999 Jan;29(1):12-6
10092983
Biochemistry. 1999 Aug 10;38(32):10361-70
10441130
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7059-64
10359838
Expert Opin Investig Drugs. 2001 May;10(5):971-80
11322870
Circulation. 1998 Sep 22;98(12):1184-91
9743509
Am J Cardiol. 1997 Jul 15;80(2):207-9
9230162